Physician profile
Patrick N Harding
NPI 1467424556
$23,115.17
in general payments reported to CMS, 2019-2025
44 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,911 · 2020: $797 · 2021: $12K · 2022: $4,834 · 2023: $1,430 · 2024: $616 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842 · Travel and Lodging: $496 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.28 |
| Travel and Lodging | $495.81 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $12,182.26 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $4,834.20 | 2022 | |
| Inspire Medical Systems, INC. | $2,056.90 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $604.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $471.02 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $380.26 | 2019-2020 | |
| Biogen, INC. | $195.56 | 2019-2020 | |
| Genzyme Corporation | $193.90 | 2019-2020 | |
| Amgen INC. | $187.11 | 2019 | |
| Eisai INC. | $184.84 | 2019-2025 | |
| Allergan, INC. | $182.32 | 2019-2020 | |
| Ucb, INC. | $172.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $168.08 | 2019-2020 | |
| Emd Serono, INC. | $132.24 | 2019-2020 | |
| Genentech USA, INC. | $110.04 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.